Image

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Exploring new CAR-T therapy for tough-to-treat leukemia cases.

Recruiting
18 years and older
All
Phase 1
  • Simplified description (AI rewritten)
  • Technical description (Original)

Study Overview: This study focuses on a special treatment called CB-012, which uses CRISPR technology to modify immune cells (CAR-T cells) that target a molecule called CLL-1. It's for people with a type of blood cancer called Acute Myeloid Leukemia (AML)

  • Length & Visits: This is a Phase 1 study, focusing on safety and effects, with frequent medical visits.
  • Compensation: Participants may receive compensation for their time and travel.
  • Risks: Possible risks include reactions to the treatment and other side effects.

Eligibility: Participants need to have a confirmed AML diagnosis, a good physical condition, and no more than 3 previous treatments. They must also use effective birth control if they are of child-bearing potential.

Exclusions: Individuals with certain conditions like active infections, prior CAR-T treatment, or recent transplants may not be eligible. Other criteria may also apply.

Print
Study details
    Acute Myeloid Leukemia
    in Relapse
    Acute Myeloid Leukemia Refractory

NCT06128044

Caribou Biosciences, Inc.

13 December 2024

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Race
Ethnicity
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.